🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 27 of 857 · Phase 3 first, then by program name

  1. BI 764198

    Boehringer Ingelheim

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    1 trial

  2. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  3. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  4. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  5. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  6. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  7. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  8. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  9. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  10. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  11. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  12. BIIB111

    Biogen

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  13. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials

  14. BIOTIN, Medebiotin Fuerte solución inyectable, Medebiotín Fuerte Comprimidos

    The George Institute

    Metilcrotonilglicinuria, biotinidasa deficit

    phase 3 small molecule active

    1 trial

  15. BIPAP Synchrony

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 other completed

    1 trial

  16. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  17. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  18. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA (Morquio A Syndrome)

    phase 3 small molecule completed

    1 trial

  19. BMN 110 - Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IV A

    phase 3 small molecule completed

    1 trial

  20. BMN 110 Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 3 small molecule completed

    1 trial

  21. BMN 111

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    6 trials

  22. BMN 165

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 3 small molecule completed

    1 trial

  23. BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  24. BMN 333, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection, BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources